Although diffuse large B-cell lymphoma (DLBCL) represents a paradigm of highly curative disease with a complete remission (CR) rate of ≈ 60%–70% in an upfront setting, the remaining 30%–40% of patients present a relapse/refractory setting. These population are highly critical and amended for salvage treatment approach. Novel appro...

By Ivan Petković, Marija Elez, Aleksandar Popović, Slavica Stojnev, Irena Conic, Miljana Džunić, Dane Krtinić